| Hepatitis C, Chronic
Epclusa vs Harvoni
Side-by-side clinical, coverage, and cost comparison for hepatitis c, chronic.Deep comparison between: Epclusa vs Harvoni with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsHarvoni has a higher rate of injection site reactions vs Epclusa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Harvoni but not Epclusa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Epclusa
Harvoni
At A Glance
Oral
Once daily
NS5B polymerase and NS5A inhibitor
Oral
Once daily
NS5A inhibitor + NS5B polymerase inhibitor
Indications
- Hepatitis C, Chronic
- Hepatitis C, Chronic
Dosing
Chronic Hepatitis C (genotypes 1-6, without cirrhosis or compensated cirrhosis) One 400 mg/100 mg tablet orally once daily for 12 weeks (adults); weight-based dosing for pediatric patients 3 years and older (150 mg/37.5 mg for <17 kg, 200 mg/50 mg for 17-<30 kg, 400 mg/100 mg for >=30 kg) once daily for 12 weeks.
Chronic Hepatitis C (genotypes 1-6, with decompensated cirrhosis Child-Pugh B or C) One 400 mg/100 mg tablet orally once daily plus weight-based ribavirin (1,000 mg/day if <75 kg, 1,200 mg/day if >=75 kg, divided twice daily) for 12 weeks.
HCV/HIV-1 coinfection Follow dosing recommendations as above based on cirrhosis status.
Liver transplant recipients (without cirrhosis or compensated cirrhosis) One 400 mg/100 mg tablet orally once daily for 12 weeks.
Hepatitis C, Chronic (Genotype 1, treatment-naive or treatment-experienced without cirrhosis or with compensated cirrhosis) 90 mg ledipasvir/400 mg sofosbuvir orally once daily for 12 weeks (8 weeks may be considered in treatment-naive patients without cirrhosis with HCV RNA <6 million IU/mL); 24 weeks in treatment-experienced with compensated cirrhosis
Hepatitis C, Chronic (Genotype 1, with decompensated cirrhosis) 90 mg ledipasvir/400 mg sofosbuvir orally once daily + ribavirin for 12 weeks
Hepatitis C, Chronic (Genotype 1 or 4, liver transplant recipients) 90 mg ledipasvir/400 mg sofosbuvir orally once daily + ribavirin for 12 weeks
Hepatitis C, Chronic (Genotype 4, 5, or 6, without cirrhosis or with compensated cirrhosis) 90 mg ledipasvir/400 mg sofosbuvir orally once daily for 12 weeks
Contraindications
- Contraindications applicable to ribavirin when used in combination with EPCLUSA (refer to ribavirin prescribing information)
- When administered with ribavirin, all contraindications to ribavirin apply to the combination regimen
Adverse Reactions
Most common (>=10%) in subjects without cirrhosis or compensated cirrhosis Headache, fatigue
Most common (>=10%) in subjects with decompensated cirrhosis (with ribavirin) Fatigue, anemia, nausea, headache, insomnia, diarrhea
Most common (>=10%) in HCV/HIV-1 coinfected subjects Fatigue, headache
Additional reactions (5-<10%) in subjects without cirrhosis or compensated cirrhosis Nausea, asthenia, insomnia, irritability
Less common (<5%) in subjects without cirrhosis or compensated cirrhosis Rash, depressed mood
Less common (<10%) in subjects with decompensated cirrhosis Rash
Serious Serious symptomatic bradycardia when coadministered with amiodarone
Postmarketing Serious symptomatic bradycardia with sofosbuvir-containing regimens and amiodarone, skin rashes with blisters or angioedema-like swelling, angioedema
Most common (>=10%) Fatigue, headache
Serious Serious symptomatic bradycardia when coadministered with amiodarone
Postmarketing Skin rashes, sometimes with blisters or angioedema-like swelling, angioedema
Pharmacology
Sofosbuvir is a nucleotide prodrug that inhibits HCV NS5B RNA-dependent RNA polymerase by incorporating into viral RNA and acting as a chain terminator. Velpatasvir inhibits the HCV NS5A protein required for viral replication.
Ledipasvir inhibits the HCV NS5A protein required for viral replication, and sofosbuvir inhibits the HCV NS5B RNA-dependent RNA polymerase, which is also required for viral replication.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Epclusa
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (1/12) · Qty limit (11/12)
Harvoni
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Epclusa
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (4/8)
Harvoni
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (4/8) · Qty limit (7/8)
Humana
Epclusa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Harvoni
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Epclusa.
No savings programs available for Harvoni.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EpclusaView full Epclusa profile
HarvoniView full Harvoni profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.